Smart patch may replace finger sticks for hospital insulin dosing
NCT ID NCT07194642
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether a continuous glucose monitor (CGM) can safely guide insulin therapy in cancer and transplant patients who are not in the ICU but need IV insulin due to steroids and nutrition. About 80 participants will be randomly assigned to CGM-guided care or standard hourly finger-stick checks. The goal is to see if CGM improves glucose control, reduces low blood sugar, and is preferred by nurses and patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dexcom G7 continuous glucose monitor
- What this could lead to
- If successful, this could make insulin dosing safer and more convenient for hospitalized patients with diabetes who are not in the ICU.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The device measures glucose in interstitial fluid, which can lag behind blood glucose, potentially affecting accuracy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>19 years old * Patients with diabetes or stress induced hyperglycemia requiring continuous insulin infusion therapy, with anticipated duration of this therapy being \> 24 hours. Specifically, we will include * Patients with Type 2 diabetes; or if not previously diagnosed as having diabetes, HbA1c \>7.0% (laboratory-measured at or since hospital admission or within prior 3-months). * Type 1 diabetes, as well as atypical forms of diabetes (including pancreatectomy and pancreatitis) and * Stress hyperglycemia defined as at least 1 blood glucose measurement \>180 mg/dL since admission in a patient without history of diabetes, if CII is indicated per treating physician * Insulin drip (CII) already initiated since admission or planned to be initiated * Non-critical hospitalization with expected duration of CII \> 24 hours at time of randomization * Oncology and post-transplant population receiving IV insulin therapy Exclusion Criteria: * Inability to provide written consent * Medically unstable patients receiving pressor therapy and ICU level of care. * Patients transferred from ICU with an expected requirement for CII \> 24 hours on a non-ICU floor are eligible) * For women of childbearing potential: currently pregnant or breastfeeding * Hypoxia (O2 saturation \< 90 %) present at time of potential enrollment * Hemoglobin \< 7 mg/dL; * Anasarca present at time of potential enrollment * Use of hydroxyurea or high dose acetaminophen use of \>4g daily as those are substances known to interfere with CGM system. * eGFR \< 20 mL/min or dialysis being received or planned * Known allergy to medical grade adhesives or a skin condition that may impact CGM performance per investigator discretion * Admission for Diabetic ketoacidosis or hyperosmolar hyperglycemic state Nurse Participants: * Adults aged 19 and older involved in the routine care of the patient participants * Adequate proficiency to understand and provide informed consent in English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Heartbeat test aims to catch hidden nerve damage in diabetes
- Can skin sensors replace finger pricks for diabetes care in kenya?
- Can Home-Delivered meals help control diabetes?
- Can mindfulness and yoga rewire diabetes habits?
- New pill takes aim at blood sugar in diabetes